Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Allison

Showing results (561-570 of 647) with videos related to

Pageof 65
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Cancer Immunology Research|May 20, 2024
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and MyositisBilal A Siddiqui, Nicolas L Palaskas, Sreyashi Basu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platformSiddhant U Jain, Kaylyn E Williamson, Alexander W Ying, et al.
Nature Medicine|August 30, 2011
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoVinod P Balachandran, Michael J Cavnar, Shan Zeng, et al.
Cancer Immunity|January 8, 2010
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyJianda Yuan, David B Page, Geoffrey Y Ku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid TumorsGeorge D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2011
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabJianda Yuan, Matthew Adamow, Brian A Ginsberg, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Pageof 65

Showing results (561-570 of 647) with videos related to

Sort By:
Pageof 65
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Cancer Immunology Research|May 20, 2024
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and MyositisBilal A Siddiqui, Nicolas L Palaskas, Sreyashi Basu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platformSiddhant U Jain, Kaylyn E Williamson, Alexander W Ying, et al.
Nature Medicine|August 30, 2011
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoVinod P Balachandran, Michael J Cavnar, Shan Zeng, et al.
Cancer Immunity|January 8, 2010
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyJianda Yuan, David B Page, Geoffrey Y Ku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid TumorsGeorge D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2011
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabJianda Yuan, Matthew Adamow, Brian A Ginsberg, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Pageof 65